Table 1.
Clinical information pertaining to the stage and receptor status of all 93 subjects, including that of the subjects misclassified by the F1 prognostic biomarker model.
| Group | No. of subjects | Stage I | Stage II | Stage III | Unknown stage | ER(+) | ER(−) | PR(+) | PR(−) | HER2(+) | HER2(−) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A. Discovery | |||||||||||
| R | 10 | 0 | 2 | 5 | 3 | 2 | 8 | 1 | 9 | 3 | 7 |
| NR | 40 | 6 | 16 | 14 | 4 | 27 | 13 | 25 | 15 | 4 | 36 |
| B. Validation | |||||||||||
| R | 10 | 0 | 1 | 7 | 2 | 2 | 8 | 1 | 9 | 4 | 6 |
| NR | 33 | 5 | 13 | 10 | 5 | 20 | 13 | 17 | 16 | 4 | 29 |
| C. Misclassified subjects | |||||||||||
| Discovery | |||||||||||
| R | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 |
| NR | 4 | 1 | 1 | 2 | 0 | 2 | 2 | 2 | 2 | 0 | 4 |
| Validation | |||||||||||
| R | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| NR | 2 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 2 |
Notes: The information and the results shown in Table 1 provide evidence that the accuracy of the F1 prognostic biomarker model is independent of the receptor status of the subject. A. Clinical information pertaining to the stage and receptor status of the 50 subjects [10 responders (R) and 40 nonresponders (NR)] used in the discovery study. B. Clinical information pertaining to the stage and receptor status of the 43 unknown subjects [10 responders (R) and 33 non-responders (NR)] used in the validation study. C. Clinical information pertaining to the stage and receptor status of all 8 subjects (5 in the discovery study and 3 in the validation study) misclassified by the F1 prognostic biomarker model.